Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06088264 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06088264 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 8 participants.
The verdict
NCT06088264, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the drug levels, metabolism, and removal of BMS-986322 in healthy adult male participants.
Interventions
- DRUG BMS-986322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-10-31 |
| Est. Completion | 2023-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06088264
The ClinicalTrials.gov registry entry for NCT06088264 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986322 is the first listed.
NCT06088264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06088264 about?
NCT06088264 is a clinical study titled "A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants". The purpose of this study is to evaluate the drug levels, metabolism, and removal of BMS-986322 in healthy adult male participants.
What is the current status of trial NCT06088264?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-10-31. Estimated completion is 2023-12-22.
What interventions are being tested in trial NCT06088264?
The interventions under investigation include: BMS-986322 (DRUG).
Who is sponsoring clinical trial NCT06088264?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.